AstraZeneca to invest $3.5 billion in the United States
British-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the United States by the end of 2026 to expand the company's research and manufacturing footprint.
The investment includes a new R&D center in Cambridge, Massachusetts, a biologics manufacturing facility in Maryland, and expanded cell therapy production capabilities on the West and East Coasts and specialty products in Texas.
AstraZeneca CEO Pascal Soriot said: "Our multi-billion dollar investment reflects the attractiveness of the U.S. business environment and the quality of its talent and innovation. By expanding our R&D and manufacturing footprint, we aim to strengthen the development of cutting-edge therapies and support U.S. leadership in medical innovation."
AstraZeneca said the planned investments in the United States are part of its goal of achieving $80 billion in total revenue by 2030. AstraZeneca said the United States is its largest market, contributing 44% of its total revenue.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
2026-07-11
-
Fine Chemicals Industry Overview Dec.2025
Insight into Structural Shifts, Capturing Long-Term Value in Fine Chemicals. Available for Permanent Download.Published in: Jan. 2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
AstraZeneca to Invest $2.5 Billion to Establish Global Drug R&D Center in Beijing
-
Ascending to the Summit: AstraZeneca Crowned as the Most Competitive MNC in China
-
Restructuring at AstraZeneca China: Leadership Changes and New Business Division
-
Bristol Myers Squibb's Acquisition Spree: Will it Boost its Cancer Drug Portfolio?
-
Is AstraZeneca's Acquisition of Gracell Biotechnologies a Game-Changer for Cell Therapy and Expansion in China?
-
FDA Approves Wainua, a Breakthrough Treatment for Rare Genetic Disease-Related Polyneuropathy
-
AstraZeneca Acquires Icosavax in $1.1 Billion Deal to Enter the RSV Vaccine Market
-
2023 Senior Management Personnel Changes of Multinational Pharmaceutical Companies in China, what's behind it? - IV
Recommend Reading
-
Eastman and Huafon Chemical to Establish Cellulose Acetate Yarn Production Plant in China
-
Japan Begins Construction of the World’s Largest Commercial Liquid Hydrogen Receiving Terminal
-
Arkema's New Singapore Plant Commences Operations, Tripling Polyamide Capacity
-
Kemira Acquires AquaBlue
-
Kemira to Expand Drinking Water Treatment Portfolio with New ACH Production Line
-
Key Events in the Epoxy Resins Industry in February 2026
-
Pirelli H1 Revenue Hits €3.5 Billion Net Income Up 14 Percent High-Value Tire Sales Surge to 80 Percent
-
Sika Strengthens Gulf Foothold with Strategic Acquisition of Gulf Seal
-
BASF Battles Market Turmoil as Profits Slide
-
CNCEC Signs Strategic Framework with Egypt for Red Sea Petrochemical Hub $1 Billion in New Contracts in 2025